Leman Biotech

Focus: Leman Biotech is an AI-enabled immunotherapy company focused on metabolically armed CAR-T and TIL cell therapies for oncology and metabolic diseases. The company is newly public (founded 2023) and based in Shenzhen, China, representing an emerging player in the competitive cell therapy space.

Oncology Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Leman Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Leman Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Metabolically Armed CD19 CAR-T cells

Diffuse Large B-cell Lymphoma

PHASE_1

Clinical Trials (1)

NCT05715606Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Phase 1

Help build intelligence for Leman Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity in a high-growth modality (metabolically armed cell therapy) with 11 active Phase 1 programs across multiple oncology indications
AI-enabled drug discovery platform differentiates approach from conventional CAR-T competitors and signals technical depth
Recently public status offers potential equity upside for early employees if pipeline advances to later phases

Watch Out For

Extremely early-stage pipeline with zero Phase 2+ programs—all 11 trials remain in Phase 1, presenting significant de-risking timeline uncertainty
Minimal hiring activity (only 1 active role in Research) and lack of disclosed financials, employee count, or funding suggest limited near-term growth or expansion capacity
No commercial infrastructure, published data (0 publications), or revenue milestones visible; execution risk is substantial for a 2023-founded company

Generated by Claude from Leman Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Metabolically Armed TIL cells

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT07106814Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

Phase 1

Metabolically Armed TIL cells.

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT07349160Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

Phase 1

Metabolically Armed EGFRvIII CAR-T cells

Glioblastoma (GBM)

PHASE_1

Clinical Trials (1)

NCT07244666Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma

Phase 1

Metabolically Armed CD19 CAR-T cells

Diffuse Large B-cell Lymphoma

PHASE_1

Clinical Trials (1)

NCT06120166Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Phase 1

Metabolically Armed CD19 CAR-T cells

Non-hodgkin Lymphoma,B Cell

PHASE_1

Clinical Trials (1)

NCT06716164Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

Phase 1

Metabolically Armed BCMA CAR-T cells.

Multiple Myeloma (MM)

PHASE_1

Clinical Trials (1)

NCT07085559Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Phase 1

Metabolically Armed CD19 CAR-T cells

Systemic Lupus Erythematosus

PHASE_1

Clinical Trials (1)

NCT06711146Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

Phase 1

Metabolically Armed CD19 CAR-T cells

Acute Lymphoblastic Leukemia

PHASE_1

Clinical Trials (1)

NCT06277011Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Phase 1

Metabolically Armed CD19 CAR-T cells

B-cell Acute Lymphoblastic Leukemia

PHASE_1

Clinical Trials (1)

NCT05747157Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Phase 1

Metabolically Armed CD19 CAR-T cells

Acute Lymphoblastic Leukemia

PHASE_1

Clinical Trials (1)

NCT06393335Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Phase 1

Metabolically Armed GPC3 CAR-T cells

Hepatocellular Carcinoma (HCC)

Phase 1

Clinical Trials (1)

NCT07487402Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 12 clinical trials

Top TAs: Oncology, Immunology

Publications: 1 in PubMed

Therapeutic Area Focus

Oncology

11 pipeline

Immunology

1 pipeline

Marketed

Pipeline

Research Publications(1)

Recent peer-reviewed publications with author affiliations at this company

IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.

The Lancet. Haematology

2025

PMID:41110448

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo